Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
Medical Oncology Department, MD Cancer Center, Madrid, Spain.
Oncologist. 2019 Jul;24(7):e597-e599. doi: 10.1634/theoncologist.2018-0776. Epub 2019 Mar 15.
In this article, we propose, based on a clinical case, the potential antitumor effect related to the inhibition of serotonin in neuroendocrine tumors (NETs). Currently, the only drug that exists for the symptomatic treatment of carcinoid syndrome refractory to somatostatin analogues is telotristat, based on its pivotal study, the TELESTAR trial. Based on the existing preclinical rationale, it seems that the inhibition of serotonin may have an antitumoral role in NETs. Briefly, serotonin may act as an autocrine growth factor of NETs, and it may also play an immunomodulatory role by enhancing macrophage polarization to an immunotolerant M2 phenotype. To our knowledge, this rationale for the possible antitumor effect of serotonin in NETs has not yet been published in the literature.
在这篇文章中，我们基于一个临床病例，提出了与抑制神经内分泌肿瘤（NETs）中的血清素相关的潜在抗肿瘤作用。目前，对于类癌综合征的症状治疗，即对生长抑素类似物耐药的情况，唯一存在的药物是基于其关键研究 TELESTAR 试验的替曲唑。基于现有的临床前理论基础，抑制血清素似乎在 NETs 中具有抗肿瘤作用。简单来说，血清素可能作为 NETs 的自分泌生长因子，它还可能通过增强巨噬细胞向免疫耐受的 M2 表型极化来发挥免疫调节作用。据我们所知，NETs 中血清素可能具有抗肿瘤作用的这一理论基础尚未在文献中发表。
